RELMADA THERAPEUTICS, INC.
Relmada Therapeutics Inc. (RLMD) stock rose 12.28% following positive clinical trial news and insider buying by CEO and CFO. The company has no revenue but a strong balance sheet with $218M in cash and no debt. Analysts note a nascent uptrend with support at $4.10 and resistance at $5.00-$5.25. The stock is up from $4.09 to $4.57 on strong volume.
Shenouda Maged (Chief Financial Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.22 ($4.20–$4.25, $0.84M total) across 2 trades over 2026-09-09 to 2026-09-10.
TRAVERSA SERGIO (Chief Executive Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.14 ($4.10–$4.18, $0.83M total) across 2 trades over 2026-09-09 to 2026-09-10.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RLMD (RELMADA THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RLMD coverage spans financial news, insider activity and earnings.
In the last 30 days, RLMD insiders filed 4 SEC Form 4 transactions — 4 purchases ($1.7M) and no sales. The most active reporter was Shenouda Maged, Chief Financial Officer, with 2 filings.
The insider buying signals confidence and provides short‑term upside momentum.
Insider buying by a senior executive may signal confidence, but the amount is modest relative to market cap.
Insider purchase signals confidence from management, modestly bullish for RLMD.
Execution-focused update with explicit IND timing and a longer cash runway, likely supporting near-term risk appetite but keeping biotech binary risk elevated.
Near-term catalyst is execution toward year-end IND submissions and subsequent Phase 3 RESCUE start; cash runway extends to 2029, reducing immediate financing risk.
AlphAI scores every news story that mentions RLMD with an AI model for sentiment and relevance, and aggregates insider trades from RELMADA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Relmada Therapeutics Inc. (RLMD) stock rose 12.28% following positive clinical trial news and insider buying by CEO and CFO. The company has no revenue but a strong balance sheet with $218M in cash and no debt. Analysts note a nascent uptrend with support at $4.10 and resistance at $5.00-$5.25. The stock is up from $4.09 to $4.57 on strong volume.
2 min readShenouda Maged (Chief Financial Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.22 ($4.20–$4.25, $0.84M total) across 2 trades over 2026-09-09 to 2026-09-10.
1 min readTRAVERSA SERGIO (Chief Executive Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.14 ($4.10–$4.18, $0.83M total) across 2 trades over 2026-09-09 to 2026-09-10.
1 min readRelmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.
6 min readRELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational
6 min readRelmada Therapeutics (NASDAQ:RLMD) reported Q1 2026 results on May 12, citing positive 12-month Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, with a 95% complete response rate, according to the company. It said it has $234 million cash and a $160 million financing, expected to fund operations through 2029, including a Phase 3 RESCUE program starting mid-2026.
3 min readMarketBeat compared Relmada Therapeutics (NASDAQ:RLMD) and Clearmind Medicine (NASDAQ:CMND). RLMD has a consensus target price of $12.00 (67.95% upside) versus CMND’s lower outlook, and RLMD is trading at a lower P/E. Institutional ownership is 45.2% for RLMD and 96.1% for CMND; beta is 0.43 for RLMD and 0.87 for CMND.
4 min readRelmada Therapeutics announced strong 12-month Phase 2 data for NDV-01 in bladder cancer, with complete response rates up to 95% and durable responses up to 80% at 12 months. The company plans to launch its Phase 3 RESCUE program in mid-2026 and has secured $234 million in funding, ensuring operations through 2029 despite increased quarterly net losses. An analyst has rated RLMD stock as a Buy with a $19.00 price target.
3 min readLeerink Partners has upgraded Relmada Therapeutics (RLMD) from Market Perform to Outperform, with an average one-year price target of $10.20 per share, suggesting a 160.54% upside. Institutional ownership in RLMD increased by 49.27% in the last quarter, and the put/call ratio indicates a bullish outlook for the company.
3 min readImage source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min read
